conclus
cwb
promis
treat
evd
resourcepoor
set
especi
earli
phase
outbreak
resourcemobil
done
even
though
sampl
size
small
evalu
randomis
result
contribut
exist
evid
convalesc
whole
blood
could
consid
use
candid
treat
evd
studi
randomis
requir
assess
efficaci
cwb
treatment
option
evd
outbreak
british
infect
associ
publish
elsevi
ltd
right
reserv
convalesc
blood
therapi
seem
readili
avail
potent
form
therapi
ebola
sinc
first
outbreak
ebola
viru
diseas
evd
less
attent
focuss
treatment
earli
sign
valu
convalesc
blood
therapi
ebola
reveal
recoveri
british
laboratori
worker
occup
exposur
evd
treatment
convalesc
serum
human
interferon
convalesc
plasma
consid
specif
treatment
ebola
evid
valu
convalesc
blood
therapi
cbt
provid
mupapa
colleagu
treat
eight
subject
cwb
one
die
treat
patient
may
alreadi
develop
antibodi
evd
recoveri
patient
wholli
attribut
cwb
could
also
rule
primari
caus
recoveri
subsequ
doubt
cast
passiv
immunotherapi
whole
blood
sadek
colleagu
prove
statist
surviv
benefit
transfus
blood
convalesc
patient
howev
statist
signific
alway
correl
clinic
signific
also
experi
conduct
test
effect
convalesc
whole
blood
monkey
infect
evd
lead
recoveri
creat
doubt
efficaci
cwb
volum
cwb
use
mlkg
may
suffici
enough
caus
recoveri
monkey
blood
use
obtain
day
reinfect
convalesc
monkey
pfu
evd
viru
despit
critiqu
especi
treat
evd
convalesc
blood
therapi
remain
plausibl
deal
hardtotreat
emerg
infecti
diseas
mode
treatment
exist
proven
evd
advent
modern
pharmaceut
humanderiv
animalderiv
convalesc
blood
standard
care
treatment
mani
pathogenmedi
toxinmedi
diseas
influenza
polio
herp
zoster
recent
time
convalesc
blood
product
use
hardtotreat
infecti
diseas
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
corona
viru
infect
merscov
success
outcom
addit
sever
pandem
influenza
viru
infect
even
ebola
benefit
cwb
onset
recent
report
cwb
ebola
report
distinct
form
convalesc
blood
therapi
cwb
use
studi
convalesc
blood
plasma
cbp
convalesc
blood
serum
cw
recent
use
treat
evd
guinea
studi
blood
serum
blood
plasma
featur
except
serum
lack
blood
clot
factor
plasma
blood
clot
factor
perform
function
passiv
immunotherapi
evd
addit
cbt
pool
human
immunoglobulin
ig
intraven
immunoglobulin
prepar
mostli
immunomodul
recombinantli
produc
monoclon
antibodi
mab
zmapp
polyclon
antibodi
pab
differ
two
mab
produc
singl
clone
b
lymphocyt
pab
secret
mixtur
b
lymphocyt
clone
cwb
easier
use
adapt
applic
resourcepoor
set
limit
kit
burden
hardtotreat
diseas
evd
blood
may
requir
screen
transfus
transmiss
infect
tti
viral
hepat
hiv
ensur
blood
safe
match
abo
blood
group
recipi
case
convalesc
plasma
use
may
requir
plasmapheresi
separ
blood
cell
liquid
plasma
use
also
igg
plasma
could
enrich
fraction
resourcepoor
environ
lack
basic
amen
prone
diseas
ebola
use
cwb
import
recognit
fact
world
health
organis
septemb
provid
interim
guidanc
evalu
cwb
cbp
treatment
evd
howev
littl
research
done
cbt
studi
done
small
sampl
size
studi
assess
effect
cwb
treatment
infect
patient
use
nonrandomis
studi
design
studi
carri
regiment
militari
hospit
wilberforc
freetown
pt
ebola
treatment
centr
hast
freetown
treatment
centr
establish
partnership
sierra
leon
moh
ministri
defenc
treatment
unit
oper
mainli
sierra
leonean
hast
unit
earlier
record
case
fatal
rate
result
treat
evd
patient
iv
fluid
im
vitamin
k
im
artemeth
iv
ceftriaxon
iv
metronidazol
ringer
lactat
dextros
salin
ibuprofen
tablet
immunoboost
nutrit
supplement
zinc
sulphat
tablet
artesunateelumefantrin
combin
therapi
tablet
oral
rehydr
salt
drug
studi
nonrandomis
doublesit
case
seri
patient
treat
convalesc
whole
blood
treat
cwb
evd
outbreak
studi
start
month
decemb
end
april
recruit
consent
patient
recruit
base
whether
will
part
studi
agre
cwb
transfus
match
blood
avail
transfus
agre
cwb
transfus
subject
agre
blood
transfus
cwb
routin
care
describ
previous
ansumana
et
al
given
patient
briefli
patient
given
iv
fluid
multivitamin
antipyret
analges
antibiot
anthelmint
antimalari
drug
deem
necessari
demograph
data
patient
clinic
stage
record
recruit
four
clinic
stage
evd
identifi
stage
characteris
fever
sore
throat
headach
stomach
ach
bodi
ach
also
call
dri
phase
stage
characteris
vomit
haematemesi
rash
dehydr
weak
eye
red
chest
pain
also
call
wet
phase
stage
mainli
characteris
bleed
reduc
level
conscious
irrespons
also
call
multiplesingl
organ
dysfunct
phase
final
stage
stage
recoveri
phase
symptom
record
form
recruit
metadata
age
sex
weight
convalesc
whole
blood
cwb
administ
within
first
h
admiss
accord
interim
guidanc
nation
health
author
blood
transfus
servic
one
unit
ml
abo
compat
blood
administ
consent
subject
period
one
four
hour
advers
reaction
transfus
prevent
advers
reaction
abo
compat
test
done
donat
blood
collect
date
record
donor
id
record
blood
bag
fig
blood
obtain
test
blood
servic
technician
sierra
leon
ministri
health
sanit
consent
blood
donor
recov
ebola
kenema
town
eastern
sierra
leon
donat
blood
obtain
three
month
recoveri
earlier
case
epidem
sierra
leon
affect
peopl
eastern
sierra
leon
easier
get
convalesc
blood
donor
recov
month
time
blood
collect
averag
age
blood
donor
year
femal
male
apart
clinic
asymptomat
test
neg
twice
pcr
ebola
prior
discharg
blood
donor
screen
use
elisa
kenema
govern
lassa
fever
laboratori
ensur
ebola
antigen
donat
blood
also
screen
transfus
transmiss
infect
tti
use
sd
biolin
standard
diagnost
seoul
korea
later
flow
immunoassay
viral
hepat
syphili
hiv
also
aler
aler
medic
co
ltd
matsudoshi
chiba
japan
case
hiv
simpl
rate
proport
use
studi
twosampl
ttest
independ
sampl
use
compar
ct
valu
patient
admiss
h
admiss
odd
ratio
mean
median
valu
comput
mean
standard
deviat
report
mean
ae
sd
ct
valu
obtain
part
realtim
pcr
result
fisherexact
probabl
comput
level
z
statist
analys
done
vassarstat
onlin
statist
app
http
vassarstatsnet
ethic
clearanc
obtain
sierra
leon
ethic
scientif
review
committe
subject
includ
studi
consent
particip
sixtynin
evd
subject
assess
ci
weak
admiss
ci
bodi
ach
admiss
ci
vomit
ci
averag
age
weight
cwbgroup
subject
year
kg
respect
male
femal
mean
age
weight
noncwb
group
subject
year
kg
respect
thirteen
male
twelv
femal
cwbgroup
took
averag
ae
day
onset
symptom
admiss
hold
centr
anoth
ae
day
admiss
ebola
treatment
unit
etu
noncwb
group
subject
took
averag
ae
day
onset
symptom
admiss
hold
centr
anoth
ae
day
admiss
etu
subject
treat
cwb
drop
studi
recov
succumb
diseas
case
fatal
rate
control
group
given
routin
treatment
without
convalesc
whole
blood
die
case
fatal
rate
patient
treat
convalesc
whole
blood
took
averag
ae
day
recov
control
patient
recov
took
averag
ae
day
recov
recoveri
mark
gradual
decreas
viral
load
treatment
ct
valu
patient
cwb
recov
record
similarli
ct
valu
five
noncwb
patient
obtain
admiss
h
transfus
admiss
ct
valu
invers
relat
viral
load
lower
ct
valu
mean
higher
viral
load
vice
versa
averag
ct
valu
admiss
ae
averag
h
transfus
ae
tabl
noncwb
averag
ct
valu
admiss
ae
averag
ct
valu
h
admiss
ae
similarli
ct
valu
seven
noncwb
subject
die
four
subject
convalesc
blood
die
obtain
averag
ct
valu
noncwb
patient
die
ae
admiss
ae
obtain
h
admiss
convalesc
blood
die
ct
valu
ae
admiss
ae
obtain
h
transfus
tabl
median
number
day
death
day
control
group
five
day
treatment
group
signific
differ
admiss
viral
load
viral
load
first
h
treatment
convalesc
whole
blood
p
reduct
viral
load
observ
subject
convalesc
blood
noncwb
group
studi
odd
ratio
surviv
cwb
ci
tabl
patient
consid
recov
two
neg
pcr
test
lack
clinic
sign
ebola
use
convalesc
whole
blood
treatment
evd
conting
avail
viabl
blood
obtain
will
recov
subject
condit
could
easili
attain
even
highli
resourceconstrain
environ
may
experi
evd
outbreak
viabil
blood
normal
determin
lack
infecti
agent
must
expir
use
transfus
must
match
blood
type
recipi
condit
could
also
met
even
resourcepoverti
studi
provid
addit
evid
convalesc
whole
blood
treatment
evd
viabl
apart
transfus
given
select
subject
subject
provid
treatment
etu
describ
previous
differ
outcom
observ
patient
treat
cwb
could
like
result
blood
therapi
viral
load
decreas
significantli
within
first
h
transfus
viral
load
chang
significantli
subject
receiv
transfus
addit
case
fatal
rate
less
subject
convalesc
whole
blood
treatment
higher
subject
without
cwb
odd
ratio
surviv
cwb
twice
ncwb
observ
viral
load
play
import
part
patient
recoveri
report
earlier
ncwb
patient
low
viral
load
recov
n
z
ct
valu
high
viral
load
die
n
z
ct
valu
surviv
rate
ncwb
group
hing
reduc
viral
load
routin
care
hand
observ
cwb
increas
surviv
rate
patient
high
viral
load
n
z
ct
valu
surviv
rate
tabl
moreov
overal
case
fatal
rate
cwb
patient
n
z
lower
report
ansumana
et
al
use
iv
fluid
support
treatment
also
lower
risk
death
patient
treat
cbp
guinea
howev
case
fatal
rate
ncwb
patient
within
rang
cfr
first
subject
treat
hast
septemb
octob
reduc
fatal
use
cwb
studi
low
case
fatal
rate
report
earlier
mupapa
colleagu
overal
also
report
reduc
fatal
rate
convalesc
whole
blood
appear
suitabl
treat
evd
resourcepoor
set
especi
earli
phase
outbreak
resourcemobil
done
studi
show
assess
viral
load
import
admit
patient
evd
case
high
viral
load
treatment
convalesc
whole
blood
benefici
recoveri
patient
studi
import
provid
addit
posit
evid
use
cbt
evd
outbreak
cbt
use
studi
freetown
sierra
leon
differ
cbp
evalu
report
guinea
risk
death
patient
risk
death
control
report
togeth
studi
show
convalesc
blood
therapi
could
use
futur
evd
outbreak
studi
sever
limit
conduct
emerg
one
limit
randomis
sampl
size
rel
smaller
compar
guinea
studi
addit
subject
treat
convalesc
whole
blood
exclus
convalesc
blood
combin
routin
support
therapi
describ
previous
low
case
fatal
rate
could
due
synergist
effect
support
therapi
cwb
unabl
get
ct
valu
subject
test
done
offsit
treatment
unit
import
futur
studi
compar
clinic
outcom
convalesc
whole
blood
convalesc
blood
plasma
treat
evd
